Cargando…

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic

Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bueno, Fernanda, Abelleira, Erika, von Stecher, Florencia, Paes de Lima, Andrea, Pitoia, Fabián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065318/
https://www.ncbi.nlm.nih.gov/pubmed/33587835
http://dx.doi.org/10.20945/2359-3997000000325
_version_ 1785018081673740288
author Bueno, Fernanda
Abelleira, Erika
von Stecher, Florencia
Paes de Lima, Andrea
Pitoia, Fabián
author_facet Bueno, Fernanda
Abelleira, Erika
von Stecher, Florencia
Paes de Lima, Andrea
Pitoia, Fabián
author_sort Bueno, Fernanda
collection PubMed
description Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
format Online
Article
Text
id pubmed-10065318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-100653182023-04-01 Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic Bueno, Fernanda Abelleira, Erika von Stecher, Florencia Paes de Lima, Andrea Pitoia, Fabián Arch Endocrinol Metab Case Report Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases. Sociedade Brasileira de Endocrinologia e Metabologia 2021-02-15 /pmc/articles/PMC10065318/ /pubmed/33587835 http://dx.doi.org/10.20945/2359-3997000000325 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Bueno, Fernanda
Abelleira, Erika
von Stecher, Florencia
Paes de Lima, Andrea
Pitoia, Fabián
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title_full Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title_fullStr Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title_full_unstemmed Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title_short Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
title_sort dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the covid-19 pandemic
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065318/
https://www.ncbi.nlm.nih.gov/pubmed/33587835
http://dx.doi.org/10.20945/2359-3997000000325
work_keys_str_mv AT buenofernanda dramaticclinicalresponsetodabrafenibplustrametinibinanaplasticthyroidcarcinomaandthechallengesfacedduringthecovid19pandemic
AT abelleiraerika dramaticclinicalresponsetodabrafenibplustrametinibinanaplasticthyroidcarcinomaandthechallengesfacedduringthecovid19pandemic
AT vonstecherflorencia dramaticclinicalresponsetodabrafenibplustrametinibinanaplasticthyroidcarcinomaandthechallengesfacedduringthecovid19pandemic
AT paesdelimaandrea dramaticclinicalresponsetodabrafenibplustrametinibinanaplasticthyroidcarcinomaandthechallengesfacedduringthecovid19pandemic
AT pitoiafabian dramaticclinicalresponsetodabrafenibplustrametinibinanaplasticthyroidcarcinomaandthechallengesfacedduringthecovid19pandemic